The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.

The secondary objectives of the study are:

  • To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population
  • To characterize concentrations of casirivimab and imdevimab in serum over time
  • To assess the immunogenicity of casirivimab and imdevimab

outside the clinical trial.  

Source link